Biologic
Allograft, autograft or no biologic had similar fusion rates in foot, ankle arthrodesis
SAN DIEGO — Results presented here showed the use of an allograft, autograft or no biologic adjuvant had equivalent fusion rates and rates of postoperative adverse outcomes in foot and ankle arthrodesis.
Hereditary angioedema attacks fall 62% with switch to donidalorsen
SAN DIEGO — Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer attacks and improved disease control, according to a poster presented here.
Dupilumab, tezepelumab lead biologic initiations for severe asthma
SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here.
Patients with severe asthma need fewer steroid bursts with tezepelumab-ekko
SAN DIEGO — Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.
On-demand sebetralstat effective for hereditary angioedema attacks in larynx
SAN DIEGO — Patients with hereditary angioedema whose attacks impacted their larynx experienced on-demand relief within 1.29 hours with oral sebetralstat, preventing potentially fatal outcomes, according to an abstract presented here.
Chronic rhinosinusitis with nasal polyps improves with tezepelumab
SAN DIEGO — Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to an abstract presented here.
Risk factors impact denials, wait times, discontinuations in biologic treatment for asthma
SAN DIEGO — Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, as well as with discontinuations, according to a series of posters presented here.
Eosinophilic granulomatosis with polyangiitis remission achieved with benralizumab
SAN DIEGO — Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here.
Twice-yearly depemokimab for asthma tolerated well as exacerbation rates fall
SAN DIEGO — Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically significant exacerbations, according to a poster abstract presented here.
Median hereditary angioedema attack rates fall to zero for children with berotralstat
SAN DIEGO — Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a median of zero after the first month and at 12 months, according to a poster presented here.